Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
Add more filters










Publication year range
1.
ACS Appl Mater Interfaces ; 14(4): 4969-4979, 2022 Feb 02.
Article in English | MEDLINE | ID: mdl-35044743

ABSTRACT

The interest in the development of nanoscale plasmonic technologies has dramatically increased in recent years. The photonic properties of plasmonic nanopatterns can be controlled and tuned via their size, shape, or the arrangement of their constituents. In this work, we propose a 2D hybrid metallic polymeric nanostructure based on the octupolar framework with enhanced sensing property. We analyze its plasmonic features both numerically and experimentally, demonstrating the higher values of their relevant figures of merit: we estimated a surface-enhanced Raman spectroscopy (SERS) enhancement factor of 9 × 107 and a SPR bulk sensitivity of 430 nm/RIU. In addition, our nanostructure exhibits a dual resonance in the visible and near-infrared region, enabling our system toward multispectral plasmonic analysis. Finally, we illustrate our design engineering strategy as enabled by electron beam lithography by the outstanding performance of a SERS-based biosensor that targets the Shiga toxin 2a, a clinically relevant bacterial toxin. To the best of our knowledge, this is the first time that a SERS fingerprint of this toxin has been evidenced.


Subject(s)
Biocompatible Materials/chemistry , Shiga Toxins/analysis , Biosensing Techniques , Gold/chemistry , Materials Testing , Metal Nanoparticles/chemistry , Particle Size , Photons , Spectrum Analysis, Raman , Surface Properties
2.
Virus Res ; 243: 31-35, 2018 01 02.
Article in English | MEDLINE | ID: mdl-29029951

ABSTRACT

Hepatitis C virus (HCV) persistence results from inefficiencies of both innate and adaptive immune responses to eradicate the infection. A functional impairment of circulating Vγ9Vδ2 T-cells was described but few data are available on Vγ9Vδ2 T-cells in the liver that, however, represents the battlefield in the HCV/host interaction. Aim of this work was to compare circulating and intrahepatic Vγ9Vδ2 T-cells in chronic HCV-infected patients (HCVpos) and in HCV-negative (HCVneg) subjects. Phenotypic and functional analysis was performed by flow cytometry. Anti-HCV activity was analyzed by using an in vitro autologous liver culture system. Independently from HCV infection, the liver was enriched of Vγ9Vδ2 T-cells expressing an effector/activated phenotype. In contrast, an enrichment of PD-1 expressing Vγ9Vδ2 T-cells was observed both in the peripheral blood and in the liver of HCVpos patients, probably due to a persistent antigenic stimulation. Moreover, a lower frequency of IFN-γ producing Vγ9Vδ2 T-cells was observed in the liver of HCVpos patients, suggesting a functional impairment in the cytokine production in HCVpos liver. Despite this hypo-responsiveness, intrahepatic Vγ9Vδ2 T-cells are able to exert an anti-HCV activity after specific stimulation. Altogether, our data show that HCV infection induced a dysregulation of intrahepatic Vγ9Vδ2 T cells that maintain their anti-HCV activity after specific stimulation. A study aimed to evaluate the mechanisms of the antiviral activity may be useful to identify new pathways able to improve Vγ9Vδ2 T-cells intrahepatic function during HCV infection.


Subject(s)
Hepacivirus/physiology , Hepatitis C/virology , Liver/immunology , T-Lymphocytes/immunology , Virus Replication , Adult , Aged , Female , Hepacivirus/genetics , Hepacivirus/isolation & purification , Hepatitis C/immunology , Humans , Interferon-gamma/genetics , Interferon-gamma/immunology , Liver/virology , Male , Middle Aged , Young Adult
3.
J Clin Pharm Ther ; 42(5): 621-623, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28474408

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: The second-generation direct-acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro-resected patients. CASE DESCRIPTION: We report on a gastrectomized patient with chronic hepatitis C infection. She was treated with sofosbuvir and ledipasvir (SOF/LDV) for 12 weeks, with measurement of blood levels of the drugs. She obtained sustained virological response at week 12 and 24 without dose adjustment. WHAT IS NEW AND CONCLUSION: This case report can provide information useful for clinical practice in this set of patients and can open new perspectives in evaluating actual SOF/LDV bioavailability.


Subject(s)
Antiviral Agents/administration & dosage , Benzimidazoles/therapeutic use , Fluorenes/therapeutic use , Gastrectomy , Hepatitis C, Chronic/drug therapy , Uridine Monophosphate/analogs & derivatives , Aged , Antiviral Agents/pharmacokinetics , Drug Combinations , Female , Humans , Sofosbuvir , Time Factors , Treatment Outcome , Uridine Monophosphate/therapeutic use
4.
Eur J Surg Oncol ; 40(8): 982-8, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24767805

ABSTRACT

BACKGROUND: The main limiting factor to major hepatic resections is the amount of the future liver remnant (FLR). Associating Liver Partition with Portal Vein Ligation for Staged Hepatectomy (ALPPS) is a procedure which induces a rapid hypertrophy of the FLR in patients with non-resectable liver tumours. METHODS: ALPPS is a surgical technique of in-situ splitting of the liver along the main portal scissura or the right side of the falciform ligament, in association with portal vein ligation in order to induce a rapid hypertrophy of the left FLR. RESULTS: The median FLR volume increase was 18.7% within one week after the first step and 38.6% after the second step. At the first step the median operating time was 300 min, blood transfusions were not required in any case, median blood loss was 150 cc. At the second step median operating time was 180 min, median blood loss was 50 cc, none of the patients required intra-operative blood. All patients are alive at a median follow up of 9 months. CONCLUSIONS: This novel strategy seems to be feasible even in the context of a cirrhotic liver, and demonstrates the capacity to reach a sufficient FLR within a shorter interval of time.


Subject(s)
Carcinoma, Hepatocellular/surgery , Hepatectomy/methods , Liver Neoplasms/surgery , Liver/blood supply , Portal Vein/surgery , Adult , Aged , Carcinoma, Hepatocellular/diagnosis , Carcinoma, Hepatocellular/etiology , Feasibility Studies , Female , Humans , Ligation , Liver/diagnostic imaging , Liver/pathology , Liver Neoplasms/diagnosis , Liver Neoplasms/etiology , Magnetic Resonance Imaging , Male , Middle Aged , Tomography, X-Ray Computed
5.
Transplant Proc ; 40(6): 1976-8, 2008.
Article in English | MEDLINE | ID: mdl-18675105

ABSTRACT

AIM: The shortage of organs for orthotopic liver transplantation (OLT) has forced transplantation centers to expand the donor pool by using donors traditionally labeled as "extended criteria donors." One such example is OLT using a donor with advanced age. MATERIALS AND METHODS: We retrospectively evaluated 10 patients who received a liver graft from cadaveric donors older than 80 years. We analyzed pretransplantation donor and recipient characteristics, as well as the evolution of the recipients. RESULTS: All 10 donors were older than 80 years (median age, 83.5; range, 80-93). No steatosis (>30%) was accepted in the older donor group. Medium follow-up was 19.5 months. The most frequent cause for OLT was hepatitis C virus (HCV) cirrhosis (8/10 patients). We had 1 case of primary nonfunction, 1 patient died immediately after surgery because of extrahepatic complications (cardiac arrest), and 2 other patients had a severe HCV recurrence and died after 1 and 2 years from OLT, respectively. Five patients had HCV recurrence and biliary complications were present in 60% of the patients. No cases of acute or chronic rejection were described. Overall survival rates after 1 and 3 years were 80% and 40%, respectively. CONCLUSIONS: Old donor age is not an absolute contraindication to OLT. Liver grafts from donors older than 80 years can be used knowing that there is a high risk of postoperative complications. Furthermore, the increased risk of developing severe HCV recurrence, related to older donor age, suggests that such livers should be used in HCV-negative recipients.


Subject(s)
Aged, 80 and over , Carcinoma, Hepatocellular/surgery , Liver Neoplasms/surgery , Liver Transplantation/mortality , Liver Transplantation/statistics & numerical data , Living Donors/statistics & numerical data , Adult , Aged , Carcinoma, Hepatocellular/virology , Female , Graft Survival , Hepatitis B/surgery , Hepatitis C/surgery , Hepatitis D/surgery , Humans , Liver Neoplasms/virology , Male , Middle Aged , Patient Selection , Retrospective Studies , Survival Analysis , Time Factors
6.
Minerva Gastroenterol Dietol ; 54(1): 31-47, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18299666

ABSTRACT

Chronic hepatitis C virus (HCV) infection poses a challenge for a growing number of infected patients who exhibit disease complications, including cirrhosis, hepatocellular carcinoma, and liver failure. Treatment with pegylated interferon (peg-IFN) plus ribavirin improves hepatic markers and eradicates the virus in about 50% of patients; however, a significant number of patients do not respond to therapy or relapse following treatment discontinuation. Several viral, hepatic, and patient-related factors influence response to IFN therapy; many of these factors cannot be modified to improve long-term outcomes. Identifying risk factors and measuring viral load early in the treatment can help to predict response to IFN therapy and determine the need to modify or discontinue treatment. Treatment options for complicated cases of chronic HCV infection are limited. Retreatment with peg-IFN has been successful in some patients who exhibit an inadequate response to conventional IFN treatment, particularly those who have relapsed. Consensus IFN, another option in treatment-resistant patients, has demonstrated efficacy in the retreatment of non-responders and relapsers. Although optimal duration of retreatment and benefits and safety of maintenance therapy have not been determined, an extended duration is likely needed. Anti protease inhibitor drugs, the new frontier of HCV treatment, are now searched as the future answer in the treatment of difficult patients. Unfortunately the results are still confined in a preliminary phase. This article reviews risk factors for HCV treatment resistance and discusses assessment and management of difficult-to-treat patients such as non responders or relapsers to previous treatment.


Subject(s)
Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/complications , Humans , Interferons/therapeutic use , Liver Transplantation , Postoperative Complications/drug therapy , Recurrence , Risk Factors
7.
Minerva Gastroenterol Dietol ; 51(1): 109-26, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15756150

ABSTRACT

Chronic hepatitis C virus (HCV) infection is an epidemic that currently represents the number one indication for liver transplantation (LTx). Hepatitis B virus (HBV) infection is associated with better outcomes following LTx since the advent of hepatitis B immune globulin and lamivudine. The impact of HCV and HBV in LTx is well known. Therapeutic interventions, however, are less standardized and often depend upon institutional protocol. This review article will provide a comprehensive review of the literature and address many issues and complications with transplantation in patients suffering from chronic liver disease as a result of HCV or HBV.


Subject(s)
Hepatitis B/surgery , Hepatitis C, Chronic/surgery , Liver Transplantation , Antiviral Agents/therapeutic use , Bilirubin/blood , Follow-Up Studies , Graft Rejection/diagnosis , Hepacivirus/genetics , Hepatitis B/blood , Hepatitis B/complications , Hepatitis B/diagnosis , Hepatitis B/drug therapy , Hepatitis B virus/genetics , Hepatitis C, Chronic/blood , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/drug therapy , Humans , Postoperative Care , Preoperative Care , Recurrence , Reoperation , Retrospective Studies , Time Factors , Treatment Outcome
8.
Transplant Proc ; 37(10): 4393-6, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16387129

ABSTRACT

INTRODUCTION: Herpes simplex virus (HSV) is seen throughout the world and can be treated with acyclovir. We present a case of fulminant hepatic failure (FHF) as a result of disseminated HSV infection in a pregnant patient during the second trimester. METHODS: The medical records of a patient suffering from HSV-related fulminant hepatic failure were collected. A review of the literature was collected and reported. RESULTS: A previously healthy female presented with fulminant hepatic failure at a local emergency room complaining of a 5-day history of fever, nausea, vomiting, and right side abdominal pain that radiated to the back. She was diagnosed with fulminant hepatic failure and progressed into a coma. The patient underwent orthotopic liver transplantation (OLT) prior to the diagnosis of HSV and then treated successfully with acyclovir. CONCLUSION: Treatment of HSV fulminant hepatitis is dependent up on early suspicion and prompt intervention. In addition, antiviral therapy may need to be lifelong.


Subject(s)
Acyclovir/therapeutic use , Antiviral Agents/therapeutic use , Herpes Simplex/complications , Liver Failure, Acute/surgery , Liver Failure, Acute/virology , Adult , Female , Hepatocytes/pathology , Herpes Simplex/drug therapy , Herpesvirus 1, Human/isolation & purification , Humans , Liver Failure, Acute/drug therapy , Postoperative Period
9.
Transplant Proc ; 36(5): 1445-8, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15251355

ABSTRACT

With the increasing success of liver transplantation (OLT), more patients above 70 years of age are being considered for OLT. There is not enough data about the predictors for survival in this patient population. We retrospectively analyzed the medical records of 33 patients at least 70 years of age who received 34 OLT from July 1995 to July 2002. There were 16 women and 17 men of mean age 73.7 years. Etiologies of end-stage liver disease (ESLD) were: HCV (17/33, 52%), cryptogenic cirrhosis (8/33, 24%), PBC (3/33, 9%), Laennec's cirrhosis (2/33, 6%), and others (3/33, 9%). According to the UNOS classification, 15/34 (44%) were status 3, 16/34 (47%) status 2, and 3/34 (9%) status 1. Among 13/33 patients who died (39%), 1-year and 3-year survival rates were 78.79% and 71.43%, respectively. Based on UNOS criteria, 4/15 (26%) were status 3; 6/16 (37%), status 2; and 3/3 (100%), status 1 (P value = .04 for status 1 patients). There was no statistical differences between the scores using the Model for End-Stage Liver Disease (MELD) among those who died (MELD (19) versus MELD (17.35) respectively (P = .50). There was a statistically significant difference in cold ischemia time (CIT) and warm ischemia time (WIT) between those who died (P = .024 and.010, respectively). These results suggest that in this group of patients UNOS status classification, CIT and WIT correlate with survival. The sample size was too small to derive a conclusion about the association with the MELD score.


Subject(s)
Aged , Liver Transplantation/physiology , Patient Selection , Adult , Age Factors , Ethnicity , Female , Humans , Liver Diseases/classification , Liver Diseases/surgery , Liver Transplantation/mortality , Male , Middle Aged , Retrospective Studies , Survival Analysis , Tissue Donors/statistics & numerical data , Treatment Outcome
10.
Transplant Proc ; 35(8): 3029-31, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14697970

ABSTRACT

UNLABELLED: Calcineurin inhibitor-related renal toxicity affects patient and graft survival in transplant recipients. Our clinical experience has revealed sirolimus to be an effective agent in treating renal insufficiency related to calcineurin inhibitor toxicity. METHODS: We performed a retrospective review of the medical records of OLT recipients suffering from chronic renal insufficiency and treated with sirolimus at the University of Miami. RESULTS: Fourteen patients (nine men and five women) of mean age 57 years who had been treated with tacrolimus for at least 30 days were converted to sirolimus after developing nephrotoxicity. Mean creatinine clearances collected on day 0, 30, 60, and 90 after conversion were 40.1 mL/min, 49.6 mL/min, 53.9 mL/min, and 51.4 mL/min, respectively. Episodes of acute cellular rejection were not increased during the sirolimus conversion. CONCLUSION: This retrospective review suggests that OLT patients suffering from tacrolimus-related renal insufficiency successfully converted to sirolimus may benefit from this therapy.


Subject(s)
Liver Transplantation/physiology , Postoperative Complications/immunology , Renal Insufficiency/immunology , Sirolimus/therapeutic use , Creatinine/blood , Female , Humans , Immunosuppressive Agents/therapeutic use , Liver Transplantation/immunology , Male , Middle Aged , Retrospective Studies
11.
Transplant Proc ; 35(3 Suppl): 209S-216S, 2003 May.
Article in English | MEDLINE | ID: mdl-12742498

ABSTRACT

BACKGROUND: Sirolimus therapy has been used in orthotopic liver transplant (OLT) recipients diagnosed with a variety of diseases; chronic graft rejection (CR), calcineurin associated renal toxicity, preemptive immune suppression, calcineurin related neurotoxicity, preemptive therapy in transplant recipients with history of hepatocellular carcinoma, and steroid resistant allograft rejection. METHODS: A search for the medical literature and experiences involving sirolimus was done. RESULTS: Several animal and human reports evaluating the use sirolimus in liver transplant recipients are found and discussed. CONCLUSION: Sirolimus has been used for multitude of indications, primarily based on anecdotal experiences. However, reports of sirolimus related side effects have decreased the transplant communities' enthusiasm towards promoting this agent as a safe immune suppression agent.


Subject(s)
Liver Transplantation/immunology , Sirolimus/therapeutic use , Creatinine/blood , Graft Rejection/prevention & control , Humans , Hyperlipidemias/chemically induced , Immunosuppression Therapy/methods , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/blood , Immunosuppressive Agents/therapeutic use , Safety , Sirolimus/adverse effects , Sirolimus/blood , Skin/drug effects , Skin/pathology , Tacrolimus/therapeutic use , Time Factors , Wound Healing
13.
Epilepsia ; 40(7): 830-6, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10403205

ABSTRACT

PURPOSE: We investigated the role of nitric oxide (NO) as a new neurotransmitter in the control of excitability of the hippocampus and the cerebral cortex, as well as the possible functional interaction between NO and the glutamate systems. METHODS: The experiments were performed on anesthetized rats. The bioelectrical activities of the somatosensory cortex and the CA1 region of the hippocampus of these rats were recorded. Pharmacologic inhibition of NO synthase (NOS) through the nonselective and brain-selective inhibitors, N-nitro-L-arginine methyl ester (L-NAME) and 7-nitroindazole (7-NI), was performed. RESULTS: The treatments caused the appearance of an interictal discharge activity in both the structures. The latency of induction and the duration of the interictal discharge activity were strictly related to the dose of NOS inhibitor used. In some cases, after L-NAME treatment at high doses, it was possible to note spike and wave afterdischarge activity in the hippocampus. All the NOS inhibitor-mediated excitatory effects were abolished by intraperitoneal (i.p.) pretreatment with the N-methyl-D-aspartic acid (NMDA) receptor antagonists (DL-2-amino-5-phosphonovaleric acid, 2-APV; dizolcipine, MK-801) and partly suppressed after the i.p. injection of the non-NMDA antagonist (6-cyano-7-nitroquinoxaline-2,3-dione; CNQX). CONCLUSIONS: All data showed that the reduction of NO levels in the nervous system causes the functional prevalence of the excitatory neurotransmission, which is probably due to an NMDA overactivity caused by the absence of the NO-mediated modulatory action. Thus, it is possible to hypothesize a neuroprotective role for NO, probably through a selective desensitization of the NMDA receptors.


Subject(s)
Cerebral Cortex/physiopathology , Epilepsy/physiopathology , Glutamic Acid/physiology , Hippocampus/physiopathology , Nitric Oxide/physiology , Animals , Cerebral Cortex/drug effects , Epilepsy/chemically induced , Hippocampus/drug effects , Male , Rats , Rats, Wistar , Receptors, N-Methyl-D-Aspartate/drug effects , Receptors, N-Methyl-D-Aspartate/physiology , Somatosensory Cortex/drug effects , Somatosensory Cortex/physiopathology
14.
J Neural Transm (Vienna) ; 104(6-7): 615-31, 1997.
Article in English | MEDLINE | ID: mdl-9444562

ABSTRACT

The study has shown an excitatory influence exerted by lateral habenula (LH) on hippocampal pyramidal cells. The modulatory influence is paradoxically serotonine-mediated; in fact all LH stimulation effects were abolished by intrahippocampal iontophoretic methysergide application. The data suggest the involvement of dorsal raphe nucleus. In fact, the dorsal raphe nucleus stimulation caused on hippocampus an expected inhibitory effect antagonized by intrahippocampal iontophoretic methysergide application. In the context of this neural structure we have highlighted a disinhibitory relation between two types of cells: slow serotonergic efferent neurones and fast GABAergic interneurones. The disinhibitory hypothesis is also supported by the following experimental tests performed on both slow and fast raphe cells: a) LH stimulation at low and high frequencies; b) iontophoretic administration of NMDA and GABA; c) LH stimulation during intraraphe iontophoretic injection of 2-APV (NMDA antagonist) and bicuculline (GABA antagonist).


Subject(s)
Habenula/physiology , Neurons/physiology , Pyramidal Cells/physiology , Raphe Nuclei/physiology , 2-Amino-5-phosphonovalerate/pharmacology , Animals , Bicuculline/pharmacology , Cell Communication/drug effects , Cell Communication/physiology , Electric Stimulation , GABA Antagonists/pharmacology , Habenula/drug effects , Iontophoresis , Male , N-Methylaspartate/antagonists & inhibitors , N-Methylaspartate/pharmacology , Neurons/drug effects , Pyramidal Cells/drug effects , Raphe Nuclei/cytology , Raphe Nuclei/drug effects , Rats , Rats, Wistar
15.
Brain Res Bull ; 41(1): 47-52, 1996.
Article in English | MEDLINE | ID: mdl-8883915

ABSTRACT

Previously, we have demonstrated that lateral habenula (LH) modulates the bioelectric activity of the hippocampus through the dorsal raphe nucleus functional involvement. In this study we have, preliminarily, electrophysiologically identified two types of raphe neurons: "slow" (S cells, serotonergic in nature); and "fast" (F cells, presumably GABAergic in nature). Then, we have shown that LH electrical stimulation at lower frequency induced an excitation of S and F neurons. LH stimulation at higher frequency inhibited only S neurons. Furthermore, iontophoretic NMDA excited S and F neurons. The excitatory effects of LH stimulation were antagonized by the iontophoretic 2-APV (NMDA antagonist). Iontophoretic GABA inhibited only S neurons. Iontophoretic bicuculline antagonized the LH-induced inhibition os S neurons. The data suggested a direct (NMDA-mediated) and indirect (through the F GABAergic inhibitory interneuron) influence of the LH on the serotonergic efferent neuron.


Subject(s)
Habenula/physiology , Raphe Nuclei/physiology , 2-Amino-5-phosphonovalerate/pharmacology , Action Potentials/physiology , Animals , Bicuculline/pharmacology , Electrophysiology , Excitatory Amino Acid Agonists/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , GABA Antagonists/pharmacology , Habenula/cytology , Habenula/drug effects , Iontophoresis , Male , N-Methylaspartate/pharmacology , Neurons/drug effects , Neurons/physiology , Raphe Nuclei/cytology , Raphe Nuclei/drug effects , Rats , Rats, Wistar , gamma-Aminobutyric Acid/pharmacology
16.
Arch Physiol Biochem ; 103(1): 59-63, 1995 Apr.
Article in English | MEDLINE | ID: mdl-8574779

ABSTRACT

In previous experimental studies, carried out on cats, we demonstrated that electrical stimulation of lateral habenula (LH) at 0.5-3.0 Hz or 5-20 Hz had a double effect (low frequency-excitation; high frequency-inhibition) on the spontaneous firing rate of single hippocampal neurones. Our results, in agreement with similar case studies, allowed us to hypothesise that in the habenular modulation of the hippocampus the raphe nucleus is probably involved. In fact, all the effects of LH stimulation were antagonised by the iontophoretic intrahippocampal application of methysergide. In the present series of experiments, performed on rats, it was possible to demonstrate that LH stimulation at 1-10 Hz causes an excitation of a progressively major number of hippocampal neurones depending upon the increase of frequency stimulation. The absence of habenulo-induced effects after a iontophoretic application of methysergide on single hippocampal units suggests the involvement of the raphe nucleus. Furthermore, in consideration of recent anatomical evidences demonstrating an excitatory projection between LH and raphe nucleus, intraraphal N-methyl-D-aspartate (NMDA) application, performed through a Hamilton microsyringe, induces an inhibitory effect. All the results suggest that in the raphe context it is possible to hypothesise the presence of an intrinsic interneurone, directly activated by the excitatory projection arising from the LH; this interneurone is likely inhibitory on the serotonergic raphe-hippocampus efferent neurone. This functional organization is responsible for the effect of LH stimulation at different frequencies as well as for the effects of intraraphal NMDA application.


Subject(s)
Cochlea/physiology , Hippocampus/physiology , Neurons/physiology , Animals , Electric Stimulation , Electrophysiology , Hippocampus/drug effects , Iontophoresis , Male , Methysergide/administration & dosage , Methysergide/pharmacology , N-Methylaspartate/pharmacology , Raphe Nuclei/drug effects , Raphe Nuclei/physiology , Rats , Rats, Wistar , Serotonin/physiology
17.
Brain Res Bull ; 36(6): 539-43, 1995.
Article in English | MEDLINE | ID: mdl-7757487

ABSTRACT

In previous works we studied, on cats, the effects of lateral habenula (LH) stimulation on hippocampal units. In particular, the results showed an excitation or an inhibition in relation to the stimulation frequency (0.5-3.0 Hz or 5.0-20 Hz, respectively). All the LH stimulation effects were antagonised by iontophoretic intrahippocampal application of methysergide (MS). In this series of experiments it was possible to demonstrate, on rats, that LH stimulation causes an excitatory effect in a major number of hippocampal units in relation to the frequency increase. The inhibitory effect by iontophoretic serotonine application and the reversible blockade of habenular modulation after iontophoretic methysergide administration on hippocampal units suggest, on rats, the involvement of raphe. Such hypothesis, with anatomical evidences demonstrating an excitatory projection between LH and raphe, was confirmed by data concerning the effects of intraraphal NMDA iontophoretic application on hippocampal units (NMDA application for 30 s = excitation; NMDA administration for 10-15 min = inhibition). All the results suggest an habenular modulation of hippocampus through the involvement of the raphe in the context of which an interneurone is inhibitory on the efferent serotonergic raphe-hippocampus projection. This hypothesis finds further support from MS blockade effect during intraraphal NMDA iontophoretic administration.


Subject(s)
Hippocampus/drug effects , Neurons/drug effects , Raphe Nuclei/drug effects , Thalamus/drug effects , Analysis of Variance , Animals , Electric Stimulation , Hippocampus/cytology , Hippocampus/physiology , Iontophoresis , Male , Methysergide/pharmacology , Micromanipulation , N-Methylaspartate/pharmacology , Neurons/physiology , Raphe Nuclei/physiology , Rats , Rats, Wistar , Serotonin/pharmacology , Thalamus/physiology
18.
Arch Int Physiol Biochim Biophys ; 99(3): 275-9, 1991 Jun.
Article in English | MEDLINE | ID: mdl-1717065

ABSTRACT

In the cat, the effects of lateral habenula stimulation, at different ranges of frequency, on hippocampal units were studied. Habenular stimulation at low frequency excited, while at high frequency inhibited the greater part of hippocampal units. Moreover, in order to clarify the possible pathway involved in the habenulo-hippocampal circuit, the effects of iontophoretic acetylcholine and serotonin on hippocampal units were compared with those of habenular stimulation. Iontophoretic acetylcholine induced both excitatory and inhibitory responses while serotonin induced only inhibitory responses. Iontophoretic atropine blocked the effects of acetylcholine ejection but did not antagonize stimulation effects; ion-tophoretic methysergide induced an increase of basal firing of hippocampal units and antagonized both serotonin and habenular stimulation inhibition. The results suggest an influence of lateral habenula to the hippocampus which does not appear to be cholinergically-mediated. A possible involvement of the raphe as a relay station in the habenulo-hippocampal pathway is discussed.


Subject(s)
Hippocampus/physiology , Thalamus/physiology , Acetylcholine/administration & dosage , Acetylcholine/pharmacology , Animals , Atropine/administration & dosage , Atropine/pharmacology , Cats , Electric Stimulation , Electrophysiology , Hippocampus/drug effects , Iontophoresis , Methysergide/administration & dosage , Methysergide/pharmacology , Neural Pathways/physiology , Neurons/physiology , Serotonin/administration & dosage , Serotonin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...